Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06769698 | RECRUITING | Head and Neck Squamous Cell Carcinoma (HNSCC)

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor:

Regeneron Pharmaceuticals

Brief Summary:

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form. The study is focused on participants with head and neck cancers who have not been previously treated for head and neck cancer that has come back or spread to other parts of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) individually (which could make the study drugs less effective or could lead to side effects) * Compatible research to better understand the study drugs and HNSCC

Condition or disease

Head and Neck Squamous Cell Carcinoma (HNSCC)

Intervention/treatment

FDC fianlimab+cemiplimab

Cemiplimab

Placebo

Phase

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 120 participants
Masking : QUADRUPLE
Primary Purpose : TREATMENT
Official Title : Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression
Actual Study Start Date : 2026-03-31
Estimated Primary Completion Date : 2028-06-04
Estimated Study Completion Date : 2030-12-28

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Key Inclusion Criteria
  • 1. Have histologically confirmed (by local pathology) R/M HNSCC that is considered incurable by local therapies
  • 2. Primary tumor location of oral cavity, oropharynx, larynx, or hypopharynx (patients with cervical neck node SCC with occult primary as described in the protocol
  • 3. PD-L1 expression Combined Positive Score (CPS) ≥1 documented with a previously PD-L1 obtained Immunohistochemistry (IHC) result prior to screening, as described in protocol
  • 4. Oropharynx cancer participants only: HPV status, based on a previously documented result prior to screening, must have been established in a surgical biopsy specimen or a core biopsy specimen as described in the protocol
  • 5. At least 1 lesion that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as described in the protocol
  • 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • 7. Adequate organ and bone marrow function as described in the protocol
  • Key Exclusion Criteria
    • Medical Conditions
    • 1. Participants who have Progressive Disease (PD) within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC as described in the protocol
    • 2. Participants who have a primary tumor site of nasopharynx, paranasal sinus or salivary gland (any histology)
    • 3. Head and neck SCC with unknown primary site as described in the protocol
    • 4. Participants with active, known, or suspected autoimmune disease that has required systemic therapy within 5 years of the projected enrollment date as described in the protocol
    • 5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management
    • 6. History or current evidence of significant cardiovascular disease including, myocarditis, congestive heart failure (as defined by New York Heart Association Functional Classification III and IV), unstable angina, serious uncontrolled arrhythmia, and myocardial infarction 6 months prior to study enrollment.
    • Prior/Concomitant Therapy
    • 7. Participants who have received prior systemic anticancer therapy in the R/M HNSCC setting as described in the protocol
    • 8. Participants with a condition requiring corticosteroid therapy (\>10 mg prednisone/prednisolone/day or equivalent) within 14 days of the first dose of study drug as described in the protocol
    • Note: Other protocol defined Inclusion/ Exclusion Criteria apply
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Location Details

NCT06769698

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Nebraska

Oncology Hematology West P.C. dba Nebraska Cancer Specialists

Omaha, Nebraska, United States, 68130

RECRUITING

United States, Texas

Joe Arrington Cancer Research & Treatment Center

Lubbock, Texas, United States, 79410